GHO Capital, CBC Group to merge, forming what could be the largest healthcare specialist investor
Reynald Castaneda / endpoints - European healthcare investor GHO Capital and asset management firm CBC Group are set to join forces, with the new entity to manage over $21 billion. In a Wednesday release, they said ...
AI Summary: GHO Capital and CBC Group have agreed to combine their healthcare investment platforms to create roughly a $21 billion specialist investor focused on health assets. The tie-up consolidates capital and deal teams to chase larger transactions across care delivery, pharma and tech—because apparently healthcare needed a bigger private-equity behemoth.
Common asthma drug helps fight hard-to-treat cancers, including aggressive breast cancers, early study finds
livescience - Scientists found that blocking a protein best known for its role in asthma enhances cancer immunotherapy in preclinical models.
AI Summary: Early studies report that a widely used asthma medication can switch off a tumor immune‑evasion pathway and restore anti‑tumor immunity in models and early human data, improving responses in some hard‑to‑treat cancers including aggressive breast tumours. Researchers call for larger trials to confirm clinical benefit and safety.
- Asthma drug revives anti‑tumor immunity in resistant cancers (5)
- Mechanisms and meetings on immunotherapy resistance (5)
- All Other Stories
Asthma drug revives anti‑tumor immunity in resistant cancers
Mechanisms and meetings on immunotherapy resistance
All Other Stories
FDA Approves AstraZeneca Drug With New Approach to Lowering High Blood Pressure
Frank Vinluan / medcitynews - AstraZeneca’s Baxfendy is the first FDA-approved drug in a new class of medicines called aldosterone synthase inhibitors. The new mechanism of action is important for patients and for AstraZeneca, which has been looking for new drugs with blockbuster pote…
AI Summary: The FDA has approved a first-in-class oral agent that uses a novel mechanism to lower resistant hypertension, offering an alternative for patients who haven’t responded to standard therapies. The move expands treatment options and signals renewed industry focus on innovative vascular targets — finally something for stubborn blood pressure to complain about.
Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer
esmo - Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study
AI Summary: A randomized first‑line trial found that adding retifanlimab to standard chemotherapy meaningfully improved overall survival for patients with advanced squamous anal cancer, signaling a new immunotherapy-containing option where few exist. The data from the POD1UM‑303/InterAACT‑2 program offer clinicians a viable strategy to extend life without reinventing the wheel.
Overactive MYC helps tumors fix DNA breaks and resist chemotherapy, study finds
medicalxpress - A protein best known for driving cancer growth also helps damaged tumor cells survive by repairing their DNA, according to a new study that could influence how some cancers are treated.
AI Summary: New research reveals overactive MYC drives tumor cells to repair DNA breaks more efficiently, enabling resistance to chemotherapy. By illuminating the repair pathways MYC hijacks, the study identifies potential targets to reverse resistance and improve treatment responses — because apparently cancers read the manual on how to survive your best shot.
- MYC hijacks DNA repair to enable chemo resistance (4)
- Other molecular drivers of chemoresistance and genome instability (3)
- Tumor cell death and immunity shape chemotherapy outcomes (3)
- All Other Stories
MYC hijacks DNA repair to enable chemo resistance
Other molecular drivers of chemoresistance and genome instability
Tumor cell death and immunity shape chemotherapy outcomes
All Other Stories
Data-Driven Decision Support in Obesity Management Commission: enabling more equitable and personalized obesity care
Paul W. Franks / nature - Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04363-0Announced in this Comment and in collaboration with Nature Medicine is the convening of the Data-Driven Decision Support in Obesity Management Commission, to promote adequate sc…
AI Summary: A phase 1/2 study of CRISPR‑Cas9 CD33‑deleted allogeneic hematopoietic cell transplantation followed by gemtuzumab ozogamicin maintenance reports encouraging early signals in AML. The gene‑editing approach aims to protect donor cells from CD33‑targeted therapy, potentially enabling safer post‑transplant maintenance and offering a novel strategy to marry cellular engineering with targeted antibody therapy.
- CD33‑targeted transplant and post‑transplant maintenance (4)
- Safety and ethical scrutiny of gene editing and gene therapy (3)
- Scaling cell therapy: accreditation and expanding CAR indications (3)
- All Other Stories
CD33‑targeted transplant and post‑transplant maintenance
Safety and ethical scrutiny of gene editing and gene therapy
Scaling cell therapy: accreditation and expanding CAR indications
All Other Stories
Omid Veiseh: First-in-Human Clinical Trial of IL-2 Cytokine Factories in Refractory Ovarian Cancer
oncodaily - Omid Veiseh, Professor and CPRIT Scholar in Cancer Research at Rice University and Co-Founder and Managing Partner of RBL LLC, shared a post on LinkedIn: “Excited to publish the results […]
AI Summary: A first‑in‑human trial of implantable IL‑2 “cytokine factories” in refractory ovarian cancer reported encouraging early safety and biological activity, offering a localized immune‑stimulation strategy that may boost tumor responses while avoiding systemic toxicity. Investigators described the device‑based platform as a potential option for patients with limited alternatives, pending larger efficacy studies.
Antiviral ensitrelvir cuts risk of COVID-19 in household contacts by two-thirds, study finds
medicalxpress - The antiviral drug ensitrelvir prevents infection in household contacts of COVID-19 patients when given within 72 hours after symptom onset in the index patient, according to a Phase III randomized controlled trial published in the New England Journal of …
AI Summary: A randomized trial shows the oral antiviral ensitrelvir, used as post‑exposure prophylaxis, reduced the risk of symptomatic COVID‑19 in household contacts by roughly two‑thirds. The finding suggests a practical option for preventing spread after close exposure, offering public‑health teams a less dramatic but highly useful tool than lockdowns.
BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
Ayisha Sharma / endpoints - BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label. The FDA greenlit ...
AI Summary: BeOne Medicines secured FDA approval for a next-generation BCL2 inhibitor, positioning the drug as a direct challenge to AbbVie/Roche’s Venclexta franchise. The move reshuffles competitive dynamics in hematology, potentially offering clinicians an alternative and setting the stage for market share battles and payer negotiations. Expect aggressive positioning and head-to-head data requests.
Positive VOLGA Phase III Results for Imfinzi Plus Neoadjuvant EV in MIBC
oncodaily - On May 14, 2026, AstraZeneca announced positive high-level results from a planned interim analysis of the Phase III VOLGA trial, evaluating perioperative Imfinzi with or without Imjudo in combination with […]
AI Summary: Phase III VOLGA trial results reveal that combining durvalumab (Imfinzi) with neoadjuvant enfortumab vedotin improved survival outcomes in muscle‑invasive bladder cancer. Investigators and industry voices highlight potential practice-changing implications for perioperative therapy, while stakeholders weigh regulatory filings and integration into treatment guidelines. Clinicians will want full datasets and toxicity details.
- Clinician reactions, biology and resistance concerns (4)
- Global GU oncology meetings and community coverage (3)
- VOLGA Phase III readout and regulatory landscape (3)
- All Other Stories
Clinician reactions, biology and resistance concerns
Global GU oncology meetings and community coverage
VOLGA Phase III readout and regulatory landscape
All Other Stories
Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
Cyril Erameh / nature - Nature Medicine, Published online: 15 May 2026; doi:10.1038/s41591-026-04402-wAn open-label, randomized controlled phase 2 trial comparing favipiravir with ribavirin for the treatment of mild-to-moderate Lassa fever in Nigeria found that favipiravir was s…
AI Summary: An open-label, randomized Phase 2 trial of favipiravir for Lassa fever reported encouraging results, suggesting antiviral benefit where few options exist. The study offers early clinical proof-of-concept, especially important for endemic West African settings, and calls for larger trials to confirm efficacy, optimize dosing, and assess deployment logistics.
Supreme Court preserves access to abortion pill by mail
Sydney Halleman / healthcaredive - The ruling maintains access to mifepristone while litigation continues. The drug can still be prescribed at pharmacies or by mail without requiring in-person visits.
AI Summary: The Supreme Court intervened to maintain access to mifepristone, temporarily restoring telehealth prescribing and preserving mail distribution while litigation proceeds. The decision keeps the pill available nationwide, blocking lower-court restrictions that would have sharply limited remote access and complicated routine clinical care for patients and providers.
Bristol Myers Squibb and Hengrui Forge $15.2 Billion Strategic Alliance, Reshaping China-Out Licensing Landscape
oncodaily - Bristol Myers Squibb (NYSE: BMY) and Jiangsu Hengrui Pharma (600276.SH; 01276.HK) on Tuesday unveiled one of the largest cross-border biopharma collaborations of the year: a global strategic alliance encompassing 13 […]
AI Summary: Bristol Myers Squibb and Hengrui Pharma announced a sweeping strategic alliance covering multiple oncology assets, with potential payments and milestones that could reach roughly $15.2 billion. The deal bundles discovery, development and commercialization rights, reshaping China‑out‑licensing dynamics and signaling continued consolidation and collaboration in global cancer drug development.
Optum Rx unveils new transparent PBM model
fiercehealthcare - UnitedHealth Group's pharmacy benefit manager, Optum Rx, is making the shift to a more transparent model, the company announced Monday.
AI Summary: Optum Rx unveiled a new pharmacy benefit model that separates drug list prices from PBM fees and adopts clearer pass‑through pricing. Aimed at employers and payers fed up with opaque pharmacy economics, the proposal promises simpler contracts and fee clarity — an attempt to make PBMs boringly accountable and maybe slightly less profitable.
- Industry responses to rising drug costs and PBM models (4)
- Lawmakers and states press PBM vertical-integration reform (4)
- Optum Rx unveils transparent PBM model (4)
- All Other Stories
Industry responses to rising drug costs and PBM models
Lawmakers and states press PBM vertical-integration reform
Optum Rx unveils transparent PBM model
All Other Stories
F.D.A. Commissioner Marty Makary Resigns After Weeks of Pressure
Christina Jewett / nytimes - The agency’s top food official will step in as acting commissioner, after Dr. Makary’s tumultuous run as the nation’s top food, drug, tobacco and medical device regulator.
AI Summary: F.D.A. commissioner Marty Makary resigned after weeks of intense scrutiny and internal pressure over leadership and policy choices, following reports he faced possible removal. The agency now confronts leadership turbulence as officials rush to steady regulatory priorities, reassure stakeholders and clean up an exit that leaves unfinished reviews and awkward staff memos.
- Firing reports and buildup to Makary's ouster (4)
- Regulatory ripple effects and agency departures (3)
- Resignation announced and immediate leadership vacuum (5)
- All Other Stories
Firing reports and buildup to Makary's ouster
Regulatory ripple effects and agency departures
Resignation announced and immediate leadership vacuum
All Other Stories
A Cancer Driven by Ultra-Rare Mutation Gets Its First FDA-Approved Therapy
Frank Vinluan / medcitynews - Partner Therapeutics’ Bizengri is now FDA approved for treating advanced cases of cholangiocarcinoma driven by NRG1 gene fusions. Partner acquired U.S. rights to this bispecific antibody from Merus in 2024. The post A Cancer Driven by Ultra-Rare Mutation …
AI Summary: The FDA approved zenocutuzumab‑zbco for NRG1‑fusion–positive cholangiocarcinoma, delivering the first cleared therapy for cancers driven by this ultra‑rare genomic alteration. Trial data showed meaningful responses in heavily pretreated patients, prompting regulators to greenlight a precision option that offers targeted benefit where none existed — a small‑population win for genomic oncology.
Study reveals how parenting styles shape babies' willingness to help others
medicalxpress - New research from Durham University shows that the way parents instruct and encourage infants to help plays a key role in how helping behavior develops, and that these approaches vary across cultures.
AI Summary: The RESET‑C trial tested one preoperative dose of pembrolizumab in localized mismatch repair‑deficient colon cancer and recorded unexpectedly high tumor responses, with several patients remaining cancer‑free for nearly three years. The dramatic neoadjuvant activity suggests immune priming could reshape perioperative strategies and raises questions about surgery timing and organ preservation.
A new Medicare option for weight loss drugs is coming: Here's what to know
Jackie Fortiér / npr - Millions of people with Medicare will soon be eligible to get discounted GLP-1 drugs for weight loss. Here's how it will work.
AI Summary: Medicare is introducing a new option to expand access to weight‑loss medications for older Americans, outlining eligibility, coverage mechanics and likely impacts on beneficiaries and budgets. The guidance aims to help clinicians and patients navigate coverage decisions and prepares stakeholders for shifts in prescribing patterns and costs as demand for GLP‑1 class drugs remains high.
- Competition, dosing and long-term weight strategies (4)
- Efficacy and safety of GLP‑1s in older adults (3)
- Medicare expansion and coverage landscape (3)
- All Other Stories
Competition, dosing and long-term weight strategies
Efficacy and safety of GLP‑1s in older adults
Medicare expansion and coverage landscape
All Other Stories
UCB bets $2 billion on Candid's T cell engager ambitions
Kyle LaHucik / endpoints - Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is paying $2 ...
AI Summary: UCB has struck a roughly $2 billion deal to acquire Candid, betting heavily on Candid’s T‑cell engager platform to reset immune‑based oncology programs. The acquisition boosts UCB’s immuno‑oncology pipeline and signals intensified competition in T‑cell engager development, with investors and researchers watching closely to see how science translates into clinical wins.
The peptide problem: Hype is outrunning the evidence
medicalxpress - Health Canada recently warned Canadians not to buy or inject unauthorized peptide drugs sold online, naming products that include BPC-157, CJC-1295, ipamorelin, TB-500 and retatrutide.
AI Summary: The booming market for peptide therapies and supplements is racing past the science. Researchers report limited clinical evidence, unclear long-term safety, and weak regulatory oversight, while consumer demand and marketing hype surge. Clinicians urge caution: biological plausibility isn’t the same as proven benefit, and enthusiasm should not substitute for rigorous trials.